MX2018004831A - Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina. - Google Patents

Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina.

Info

Publication number
MX2018004831A
MX2018004831A MX2018004831A MX2018004831A MX2018004831A MX 2018004831 A MX2018004831 A MX 2018004831A MX 2018004831 A MX2018004831 A MX 2018004831A MX 2018004831 A MX2018004831 A MX 2018004831A MX 2018004831 A MX2018004831 A MX 2018004831A
Authority
MX
Mexico
Prior art keywords
fucosylated
protein
methods
making
afucosylated forms
Prior art date
Application number
MX2018004831A
Other languages
English (en)
Inventor
B Lowe John
Misaghi Shahram
R Snedecor Bradley
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2018004831A publication Critical patent/MX2018004831A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01047—GDP-mannose 4,6-dehydratase (4.2.1.47), i.e. GMD

Abstract

La presente solicitud hace referencia a métodos para producir una proteína en forma fucosilada y afucosilada con una relación predeterminada.
MX2018004831A 2015-11-02 2016-11-01 Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina. MX2018004831A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562249828P 2015-11-02 2015-11-02
US201662338280P 2016-05-18 2016-05-18
PCT/US2016/059922 WO2017079165A1 (en) 2015-11-02 2016-11-01 Methods of making fucosylated and afucosylated forms of a protein

Publications (1)

Publication Number Publication Date
MX2018004831A true MX2018004831A (es) 2018-08-01

Family

ID=57326491

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004831A MX2018004831A (es) 2015-11-02 2016-11-01 Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina.

Country Status (14)

Country Link
US (2) US10975168B2 (es)
EP (2) EP3925970A1 (es)
JP (1) JP6983772B2 (es)
KR (1) KR20180068967A (es)
CN (2) CN108431026B (es)
AU (2) AU2016350732A1 (es)
BR (1) BR112018007356A2 (es)
CA (1) CA2999047A1 (es)
ES (1) ES2875274T3 (es)
IL (1) IL258161B2 (es)
MX (1) MX2018004831A (es)
PL (1) PL3371206T3 (es)
SG (2) SG11201802773RA (es)
WO (1) WO2017079165A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016350732A1 (en) 2015-11-02 2018-04-05 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein
EP3400241B1 (en) * 2016-01-06 2020-07-22 Outlook Therapeutics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
WO2019011918A1 (en) 2017-07-10 2019-01-17 International - Drug - Development - Biotech TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
SG11202009216YA (en) * 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
MA52783A (fr) 2018-06-05 2021-04-14 Amgen Inc Modulation de la phagocytose cellulaire dépendant de l'anticorps
MY197429A (en) * 2018-08-29 2023-06-16 United Biopharma Inc Afucosylated antibodies and manufacture thereof
MX2021002792A (es) 2018-09-11 2021-05-12 Amgen Inc Metodos para modular la citotoxicidad mediada por celulas dependiente de anticuerpos.
HUP1800376A2 (hu) * 2018-11-07 2020-05-28 Richter Gedeon Nyrt Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
CN114174340A (zh) 2019-03-20 2022-03-11 加利福尼亚大学董事会 密封蛋白-6抗体和药物缀合物
CN114144434A (zh) 2019-05-06 2022-03-04 美国安进公司 调节抗体效应子功能
WO2021072244A1 (en) * 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
KR20240045239A (ko) * 2021-08-06 2024-04-05 안야디, 엘엘씨 개인 맞춤형 암 면역치료제 제조방법

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
CA2343080A1 (en) 1998-09-29 2000-04-06 Pioneer Hi-Bred International, Inc. Mar/sar elements flanking rsyn7-driven construct
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
US7259010B2 (en) 2000-12-15 2007-08-21 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region of interferon beta
EP1395669B1 (en) 2001-01-26 2009-07-22 Selexis S.A. Matrix attachment regions and methods for use thereof
HUP0600342A3 (en) * 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
ATE514783T1 (de) 2003-11-12 2011-07-15 Schering Corp Plasmidsystem zur expression mehrerer gene
EP1888638A2 (en) * 2005-06-03 2008-02-20 Genentech, Inc. Method of producing antibodies with modified fucosylation level
TWI414531B (zh) * 2006-10-12 2013-11-11 Genentech Inc 淋巴毒素α之抗體
EP3279326B1 (en) * 2009-06-02 2020-10-14 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
AU2010256455A1 (en) * 2009-06-05 2012-01-19 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
CN103597073B (zh) * 2011-03-06 2019-06-07 默克雪兰诺有限公司 低岩藻糖细胞系及其应用
WO2013013013A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
WO2015026846A1 (en) * 2013-08-19 2015-02-26 Biogen Idec Ma Inc. Control of protein glycosylation by culture medium supplementation and cell culture process parameters
DK3218490T3 (en) * 2014-11-15 2019-02-18 Zumutor Biologics Inc DNA BINDING DOMAIN OF CRISPR SYSTEM FOR PRODUCING NON-FUCOSYLED AND PARTICULAR FUCOSYLED PROTEINS
US11267899B2 (en) * 2015-05-13 2022-03-08 Zumutor Biologics Inc. Afucosylated protein, cell expressing said protein and associated methods
AU2016350732A1 (en) 2015-11-02 2018-04-05 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein

Also Published As

Publication number Publication date
IL258161A (en) 2018-05-31
AU2022202460A1 (en) 2022-05-05
AU2016350732A1 (en) 2018-04-05
EP3371206A1 (en) 2018-09-12
EP3925970A1 (en) 2021-12-22
KR20180068967A (ko) 2018-06-22
IL258161B1 (en) 2023-04-01
US11802165B2 (en) 2023-10-31
BR112018007356A2 (pt) 2018-10-23
US20210214462A1 (en) 2021-07-15
CA2999047A1 (en) 2017-05-11
JP6983772B2 (ja) 2021-12-17
ES2875274T3 (es) 2021-11-10
JP2019505164A (ja) 2019-02-28
SG10202103875WA (en) 2021-06-29
CN108431026A (zh) 2018-08-21
CN108431026B (zh) 2023-02-17
CN116731147A (zh) 2023-09-12
WO2017079165A1 (en) 2017-05-11
PL3371206T3 (pl) 2021-09-27
IL258161B2 (en) 2023-08-01
SG11201802773RA (en) 2018-05-30
US20180251572A1 (en) 2018-09-06
EP3371206B1 (en) 2021-04-14
US10975168B2 (en) 2021-04-13

Similar Documents

Publication Publication Date Title
MX2018004831A (es) Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina.
HK1246800A1 (zh) 用於營養組合物的寡糖組合物和其製造方法
AU365211S (en) Electronic cigarette component
AU355322S (en) Chair
MY190747A (en) Method for producing silazane-siloxane copolymers and the use of such copolymers
AU358035S (en) Valve
AU366399S (en) Luminaire
AU366532S (en) Electronic cigarette component
AU366529S (en) Electronic cigarette component
MX2015016603A (es) Composiciones de corticosteroides.
CA153529S (en) Dynamic mixer
EP2990035A4 (en) 1.5-ANHYDRO-D-GLUCITOL-CONTAINING COLLAGEN PRODUCTION ACCELERATOR
CA151652S (en) Applicator
TWD177663S (zh) 淨水器
HK1259370A1 (zh) 製備岩藻糖基化和去岩藻糖基化形式的蛋白質的方法
CA167034S (en) Fryer
CA167033S (en) Fryer
AU365840S (en) Egg poacher
CA153898S (en) Injector
CA157134S (en) Refrigerating apparatus
CA157132S (en) Refrigerating apparatus
CA155519S (en) Electronic autoinjector
AU365305S (en) Valve portion
AU365769S (en) Confectionery package
PH12015000061A1 (en) Eco-leather connector bracelet